🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,254 results for “First” Clear

  1. Azacitidine in Combination With Venetoclax

    First Tracks Biotherapeutics

    Hematologic Malignancy

    phase 2 small molecule active

    1 trial

  2. BGB-A317

    First Tracks Biotherapeutics

    Gastric Cancer

    phase 2 small molecule completed

    1 trial

  3. BM-MSCs

    First Tracks Biotherapeutics

    Kidney Transplantation

    phase 2 other active

    2 trials

  4. Baritinib

    First Tracks Biotherapeutics

    Intracerebral Hemorrhage

    phase 2 small molecule completed

    1 trial

  5. Becotatug Vedotin

    First Tracks Biotherapeutics

    Nasopharyngeal Carcinoma (NPC)

    phase 2 small molecule active

    1 trial

  6. Bevacizumab

    First Tracks Biotherapeutics

    Ovarian Cancer

    phase 2 small molecule active

    1 trial

  7. Bevacizumab

    First Tracks Biotherapeutics

    Malignant Pleural Effusion

    phase 2 small molecule active

    1 trial

  8. Bevacizumab

    First Tracks Biotherapeutics

    Lung, Carcinoma

    phase 2 small molecule active

    1 trial

  9. Bevacizumab Biosimilar IBI305

    First Tracks Biotherapeutics

    Post-orthotopic Liver Transplantation

    phase 2 small molecule active

    1 trial

  10. Bevacizumab combined with Oxaliplatin and TAS-102

    First Tracks Biotherapeutics

    Advanced Colorectal Cancer

    phase 2 small molecule active

    1 trial

  11. Bevacizumab+Toripalimab+gemcitabine, adjuvant with Bevacizumab and Toripalimab

    First Tracks Biotherapeutics

    Nasopharyngeal Carcinoma

    phase 2 small molecule active

    1 trial

  12. BinD19

    First Tracks Biotherapeutics

    Relapsed B-cell Acute Lymphoblastic Leukemia

    phase 2 mab active

    1 trial

  13. Blinatumomab

    First Tracks Biotherapeutics

    B-cell Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  14. Blinatumomab plus Reduced-dose Chemotherapy

    First Tracks Biotherapeutics

    Precursor B-Cell Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  15. C225 (cetuximab)

    First Tracks Biotherapeutics

    Nasopharyngeal Carcinoma

    phase 2 small molecule completed

    1 trial

  16. CAR T-cell therapy

    First Tracks Biotherapeutics

    Acute Lymphoblastic Leukemia With Failed Remission

    phase 2 mab active

    1 trial

  17. CAR-BCMA T Cells

    First Tracks Biotherapeutics

    Multiple Myeloma

    phase 2 mab active

    1 trial

  18. CAR-T

    First Tracks Biotherapeutics

    Leukemia, Lymphocytic, Chronic, B-Cell

    phase 2 mab active

    1 trial

  19. CAR-T Cells

    First Tracks Biotherapeutics

    Lung Neoplasm Malignant

    phase 2 mab active

    1 trial

  20. CAR-T treatment

    First Tracks Biotherapeutics

    Multiple Myeloma

    phase 2 mab active

    1 trial

  21. CD19 CAR-T cells

    First Tracks Biotherapeutics

    Acute Lymphoblastic Leukemia

    phase 2 mab active

    1 trial

  22. CD19 CAR-T cells and CD19 positive feeder T cells

    First Tracks Biotherapeutics

    Acute Lymphoblastic Leukemia in Remission

    phase 2 mab active

    1 trial

  23. CD25 antibody combined glucocorticoid as first-line treatment

    China SXT Pharmaceuticals

    Acute Graft Versus Host Disease

    phase 2 small molecule active

    1 trial

  24. CIK

    First Tracks Biotherapeutics

    Lung Adenocarcinoma

    phase 2 mab terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources